SCHEDULE: Deep Track Capital Exits enGene Therapeutics Stake

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have reported a 0.0% beneficial ownership of enGene Therapeutics Inc. common shares as of June 30, 2026, indicating a complete divestment.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amendment to their Schedule 13G, reporting a 0.0% beneficial ownership of enGene Therapeutics Inc. common shares as of June 30, 2026.
• This filing indicates that the reporting persons no longer hold any shares in enGene Therapeutics Inc.
• The total number of outstanding common shares of enGene Therapeutics Inc. was 66,989,466 as of June 9, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the complete divestment of shares, indicating a lack of confidence or a strategic shift away from the company.

Negatives

• The reporting persons have completely divested their holdings in enGene Therapeutics Inc., holding 0.0% of the class of securities.
• This complete exit suggests a lack of confidence in the company's future prospects or a strategic reallocation of assets by Deep Track Capital.

Risks

• The complete divestment by a significant entity like Deep Track Capital could signal underlying issues or concerns about enGene Therapeutics' future performance or strategic direction, potentially impacting investor sentiment.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from enGene Therapeutics. The outlook is inferred from the reporting persons' decision to divest their entire stake.

Industry Context

StockSavvy.ai notes that a complete divestment by an investment entity like Deep Track Capital, especially from a biotechnology company like enGene Therapeutics, often signals a significant shift in the investor's strategy or a perceived lack of future growth potential in the specific company or the broader biotech sector segment it operates in.

Stakeholder Impact

• Shareholders may view the complete exit of Deep Track Capital negatively, potentially leading to increased selling pressure and a decline in share price.
• The market may interpret this divestment as a sign of concern regarding enGene Therapeutics' future prospects.

Next Steps

• The reporting persons have completed their divestment and will likely monitor the company's performance from the sidelines.

Key Dates

Recommendation

The complete divestment by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, as reported in this Schedule 13G amendment, indicates a significant lack of confidence in enGene Therapeutics Inc. This action suggests that the reporting persons believe the stock is unlikely to appreciate or may even decline, making it prudent for other investors to consider selling their holdings.

Keywords

enGene Therapeutics, Schedule 13G, Deep Track Capital, Divestment, Beneficial Ownership, Common Shares